The offer-for-sale in Orchid Pharma by its promoter received strong response from both non-institutional (HNI) and retail investors. While the HNI portion was subscribed by 1.14 times on Thursday, the retail portion, which opened on Friday, got 3.45 times. On Wednesday, promoter Dhanuka Laboratories informed the exchanges that it would sell up to 32.8 lakh shares, representing 8.04 per cent stake. It fixed the floor price at ₹375, a huge 72 per cent discount to Wednesday’s closing price of ₹1,319.80. Shares of Orchid Pharma closed 10 per cent lower at ₹1,065.60 on the NSE on Friday.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.